Erasca, Inc. (ERAS) Balance Sheet

The sequential decline in total assets and equity is driven entirely by accumulated deficits, with retained earnings worsening from -$735.4M to -$1.1B over the same period. This trajectory indicates a balance sheet that is structurally weakening as cash is consumed without any offsetting revenue or asset growth. The absence of goodwill or significant intangibles suggests the asset base is purely cash and PPE, which is being depleted at a rate that outpaces any capital raises.

The debt reduction appears to be a deliberate paydown rather than a strategic shift, as the company has no revenue to service debt organically. With a D/E of 0.12, Erasca is not at risk of insolvency from debt, but the low leverage also means the company cannot rely on additional borrowing to fund operations without increasing financial risk. The modest debt level suggests that future funding will likely come from equity issuance, which would dilute existing shareholders.

The steady decline in PPE indicates minimal capital expenditure, consistent with a clinical-stage biotech that outsources manufacturing and relies on contract research organizations. The absence of goodwill and intangibles means the balance sheet provides no cushion for impairment risk, but also no overstatement of asset values. The asset mix is dominated by cash and short-term investments, which are being consumed by R&D, leaving the company with limited tangible assets to collateralize any future debt.

The equity base is being depleted by cumulative operating losses, with no offsetting share issuance in the recent quarters, as evidenced by the declining equity despite no buybacks or dividends. The negative retained earnings highlight that the company has never been profitable and is unlikely to be in the near term. The quality of equity is low because it is not supported by retained earnings but rather by paid-in capital from prior raises, which will require further dilution to replenish.

The current ratio of 8.29 appears strong, but it is misleading because the current assets are primarily cash that is being consumed at a rate of $30-40M per quarter. With only $42.5M in cash and equivalents, Erasca has limited buffer against operational shocks, and the high current ratio does not compensate for the lack of revenue. The liquidity position is adequate for the next few quarters but will require external financing or partnership inflows to sustain operations beyond that.